TokenPost·
PacBio Narrows 2026 Revenue Guidance, Reaffirms 2028 Cash-Flow Breakeven Goal
PacBio expects $175 million to $185 million in year-end cash and lowered its operating expense outlook to $203 million to $207 million.
More news
- TokenPostTaiwan Stocks Shed 1,873 Points and Close Below 40,000
- TokenPostManulife Declares C$0.384938 Quarterly Dividend for Series 11 Shares
- TokenPostGoldman Says Midterm Results Could Reshape AI and Data Center Rules
- Crypto BriefingAnthropic’s annualized revenue run rate tops $80 billion as IPO plans shift
- Crypto BriefingOil prices set for 12% weekly drop despite tanker attacks in Gulf
- TokenPostSK Hynix Quote Falls 11.5% Over 24 Hours to 837.2 USDT